QNCX · Quince Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 30, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 30, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross upfront proceeds from private placement financing | $115M | Second Quarter 2026 | — |
| Mean improvement in six-minute walk distance (6MWD) in combined PAH and PH-ILD evaluable populat | 81.3 | Phase 2a trial | — |
| Mean improvement in six-minute walk distance (6MWD) in PH-ILD patients | 67.4 | Phase 2a trial at 24 weeks | — |
| Mean reduction in pulmonary vascular resistance (PVR) (supine) in combined PAH and PH-ILD evalua | 28.1% | Phase 2a trial | — |
| Mean reduction in pulmonary vascular resistance (PVR) (supine) in PH-ILD patients | 33.9% | Phase 2a trial at 24 weeks | — |
| Net proceeds from private placement financing | $103.6M | Second Quarter 2026 | — |
| Placement agent and other offering expenses | $11.4M | Second Quarter 2026 | — |
| Potential additional proceeds from warrant exercise | $83M | Second Quarter 2026 | — |
| Shares of common stock outstanding | 978,022 | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QNCX
this stock
Quince Therapeutics, Inc.
|
$31.84M | — | — | — | 5.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 30, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QNCX | -9.4% | +42.3% | — | +33.9% | — |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -9.0% | +37.3% | — | +31.3% | — |